Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Short Interest Up 5.4% in January

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) was the recipient of a significant increase in short interest in January. As of January 31st, there was short interest totalling 8,250,000 shares, an increase of 5.4% from the January 15th total of 7,830,000 shares. Approximately 22.6% of the shares of the company are short sold. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is currently 5.5 days.

Ginkgo Bioworks Price Performance

NYSE DNA traded up $1.18 during trading hours on Monday, hitting $14.73. The company had a trading volume of 2,867,573 shares, compared to its average volume of 1,478,148. The company has a market capitalization of $846.38 million, a price-to-earnings ratio of -1.13 and a beta of 1.16. Ginkgo Bioworks has a 52 week low of $5.26 and a 52 week high of $64.40. The company’s 50 day moving average is $11.26.

Institutional Investors Weigh In On Ginkgo Bioworks

Institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. bought a new position in Ginkgo Bioworks in the 4th quarter worth about $980,000. OMERS ADMINISTRATION Corp purchased a new stake in Ginkgo Bioworks in the fourth quarter valued at approximately $342,000. Millennium Management LLC lifted its position in Ginkgo Bioworks by 357.4% during the fourth quarter. Millennium Management LLC now owns 670,065 shares of the company’s stock valued at $6,580,000 after purchasing an additional 523,571 shares during the last quarter. Coastal Bridge Advisors LLC grew its stake in Ginkgo Bioworks by 1,609.8% in the 4th quarter. Coastal Bridge Advisors LLC now owns 276,817 shares of the company’s stock worth $2,718,000 after buying an additional 260,627 shares in the last quarter. Finally, Balyasny Asset Management L.P. increased its holdings in shares of Ginkgo Bioworks by 277.1% in the 4th quarter. Balyasny Asset Management L.P. now owns 80,743 shares of the company’s stock worth $793,000 after buying an additional 59,334 shares during the last quarter. Hedge funds and other institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.